Treats benign prostatic hyperplasia (BPH). ANDA 204645, held by Macleods Pharmaceuticals. Tamsulosin Hydrochloride.
As of Nov 21, 2026, ANDA 204645 (Tamsulosin Hydrochloride), held by Macleods Pharmaceuticals, was first approved by FDA on Jan 20, 2017, with 3 approved supplements and 0 published complete response letters.
Tamsulosin hydrochloride capsules are indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH). Tamsulosin hydrochloride capsules are not indicated for the treatment of hypertension.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jan 20, 2017 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Tamsulosin Hydrochloride0.4MG · capsule;oral | Tamsulosin Hydrochloride | Rx |
| Jun 7, 2023 | Supplement 16Labeling · Standard review | Approved | None posted |
| Sep 23, 2019 | Supplement 9Labeling · Standard review | Approved | None posted |
| Jun 26, 2017 | Supplement 1Manufacturing | Approved | None posted |
| Jan 20, 2017 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters